Biosimilars: Where We Were and Where We Are

Author：

ISSN： 1054-3406

Source： Journal of Biopharmaceutical Statistics, Vol.24, Iss.6, 2014-11, pp. : 1154-1164

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Tuberculosis: where are we going?

By Thwaites Guy

Clinical Medicine, Vol. 6, Iss. 6, 2006-12 ,pp. : 523-525

Royal College Of Physicians

Access to resources Recommend Favorite

Where we're going, we don't need appointments: The future of telemedicine in IBD

By Patil Seema Cross Raymond

Inflammatory Bowel Diseases, Vol. 18, Iss. 11, 2012-11 ,pp. : 2199-2200

Blackwell Publishing

Access to resources Recommend Favorite

Chronic lymphocytic leukemia: where are we and where are we going?

By Ujjani Chaitra Cheson Bruce D

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 12, 2012-08 ,pp. : 1675-1677

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetic adaptation of 5-fluorouracil: where are we and where are we going?

By Boisdron-Celle Michèle

Pharmacogenomics, Vol. 13, Iss. 13, 2012-10 ,pp. : 1437-1439

Future Medicine

Access to resources Recommend Favorite

Intermediate care – where are we now?

By Harari Danielle

Clinical Medicine, Vol. 2, Iss. 5, 2002-09 ,pp. : 477-479

Royal College Of Physicians

Access to resources Recommend Favorite